Navigation Links
Vystar Corporation and Revertex Malaysia Sign Vytex(TM) NRL Production Contract
Date:4/23/2008

ATLANTA, April 23 /PRNewswire/ -- Vystar Corporation announced today that Revertex Malaysia, the world's largest producer of prevulcanized rubber lattices and post vulcanizable latex compounds, has contracted to produce Vytex(TM) natural rubber latex (NRL).

"This contract represents tremendous capacity to produce Vytex NRL and meet the growing demands of manufacturers who are currently evaluating this revolutionary product," said Vystar CEO William R. Doyle. According to Doyle, the Revertex contract accounts for tens of thousands of metric tons in Vytex NRL production. Revertex is known for its expertise in producing some of the most stable latex compounds. In addition, it supplies many of the types of manufacturers that are waiting to introduce Vytex NRL into their product lines. As part of the contract, Vystar now has the cooperation of the Revertex staff, from sales to technical support, worldwide.

Vystar's proprietary Vytex NRL process chemically modifies NRL to reduce the allergenic proteins commonly found in it. The resulting Vytex NRL represents a dramatic breakthrough in the global search for a natural rubber latex in which the antigenic proteins that trigger allergic reactions are deactivated without reducing elasticity. Published data indicate that up to 6 percent of the general public and 18 percent of health care workers have some level of latex allergy. Ongoing test results consistently show that the Vytex technology reduces antigenic proteins to levels considered undetectable by the most widely used standard tests.

"Revertex evaluation and production runs of Vytex NRL over the past year have proven both the repeatability of the production of low-protein NRL and the economic feasibility of its production. The physical and chemical properties as well as the protein levels and storage stability were outstanding," Doyle said. The cost of Vytex is significantly less than the synthetic alternatives in targeted markets of manufactu
'/>"/>

SOURCE Vystar Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
2. Brooke Franchise Corporation Announces Selected July Results
3. MedThink Communications Retained by NanoBio Corporation
4. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
5. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
6. Memry Corporation Announces Fiscal Fourth Quarter and 2007 Year End Earnings Release and Conference Call
7. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19
8. LifeQuest World Corporation Proud Contributor to Dietary Supplement Education Alliance (DSEA)
9. DTI Medical Corporation Announces Reverse Split and Other Corporate Developments
10. STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer
11. AGA Medical Corporation Receives Approval for the AMPLATZER Muscular Ventricular Septal Defect Occluder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/18/2014)... Stafford Communications , a New ... breast cancer awareness program called “Sleep Pink” on October ... pajama parties where women and men can promote awareness ... of the program, Stafford’s employees wore pink pajamas and ... Page. In exchange, Stafford Communications and the makers of ...
(Date:10/18/2014)... humans have a natural opioid system in the brain. ... Berlin, has found that the opioid system of pathological ... The work was carried out by a group of ... by the Medical Research Council. This work is being ... Berlin., Gambling is a widespread behaviour with about 70% ...
(Date:10/18/2014)... 18, 2014 Mirena lawsuits ( http://www.injurybeacon.com/mirena-iud/lawsuit/ ... sustain serious injuries when it spontaneously migrated from its ... U.S. courts, Bernstein Liebhard LLP reports. According to an ... on Multidistrict Litigation (JPML) on October 15th, at least ... litigation underway in the U.S. District Court, Southern District ...
(Date:10/18/2014)... 18, 2014 The sudden closure of ... community has left hundreds of patients scrambling for ... their care with the two closed offices of another ... have been referred to the center and now are ... and procedures. This mysterious event has left literally thousands ...
(Date:10/18/2014)... Sharon Ganzhorn, a radiologic technologist at ... she created an Amazon Wish List for a local ... only be met, but that the community would also ... in just a week’s time. , Thanks to ... and country, Ganzhorn and a team of volunteers, including ...
Breaking Medicine News(10 mins):Health News:Stafford Communications Holds Second Annual Celebration to Raise Money for Breast Cancer 2Health News:Stafford Communications Holds Second Annual Celebration to Raise Money for Breast Cancer 3Health News:Pathological gambling is associated with altered opioid system in the brain: Reduced feeling of euphoria when compared to healthy volunteers 2Health News:Mirena Lawsuit Filings Grow, as Claims Pending in Federal Litigation Exceed 1,000, Bernstein Liebhard LLP Reports 2Health News:Mirena Lawsuit Filings Grow, as Claims Pending in Federal Litigation Exceed 1,000, Bernstein Liebhard LLP Reports 3Health News:Mirena Lawsuit Filings Grow, as Claims Pending in Federal Litigation Exceed 1,000, Bernstein Liebhard LLP Reports 4Health News:New Invisalign Leader Comes to Washington Heights and the Bronx 2Health News:New Invisalign Leader Comes to Washington Heights and the Bronx 3Health News:ED Nurse at Riverside Tappahannock Hospital Orchestrates Donation of $2,500 in Pet Supplies to Local Animal Shelter 2Health News:ED Nurse at Riverside Tappahannock Hospital Orchestrates Donation of $2,500 in Pet Supplies to Local Animal Shelter 3Health News:ED Nurse at Riverside Tappahannock Hospital Orchestrates Donation of $2,500 in Pet Supplies to Local Animal Shelter 4
... Dynavax Technologies,Corporation (Nasdaq: DVAX ) announced today ... present an overview of the,company at two investor conferences ... will present at the CIBC World Markets 18th Annual,Healthcare ... ET (5:35,a.m. PT). In addition, Ostrach will present at ...
... Inc. today,announced the initiation of a phase 1 ... treatment of hypertension. AR9281 is a "first-in-class,",orally-active inhibitor ... the treatment of hypertension. The trial will enroll ... the safety, tolerability,pharmacokinetics and pharmacodynamics for single ascending ...
... Nov. 1 Amira Pharmaceuticals, Inc. announced,completion of ... Amira,s,internally discovered oral drug candidate for the treatment ... also announced the start,of a Phase 1 trial ... targets the,same inflammatory response. AM103 and AM803 ...
... NAPLES, Fla., Nov. 1 MediaBrains Inc., a ... http://www.agingcare.com . The,website will focus on the needs ... for connecting caregivers with expert information,resources, products and ... Month. The caregiver market represents one of ...
... 1, Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) the,global ... Q3 2007 Financial Highlights - Product sales up 41% ... $608.7 million; - Net cash provided by operating activities ... growth now expected to be at least 30% (Q2 guidance: ...
... - An Innovative Approach to Preventing Kidney Damage during ... ... Systems Inc. (Amex: PLC ), a,company focused on innovative cardiac ... RenalGuard,System(TM) during Renal Week, the American Society of Nephrology,s 40th,Annual Meeting ...
Cached Medicine News:Health News:Dynavax to Present at CIBC World Markets and Acumen BioFin Rodman and Renshaw Healthcare Conferences 2Health News:Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent 2Health News:Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent 3Health News:Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease 2Health News:Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease 3Health News:Agingcare.com Launches to Meet Information and Networking Demands for Booming 34 Million Caregiver Market 2Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 2Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 3Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 4Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 5Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 6Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 7Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 8Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 9Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 10Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 11Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 12Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 13Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 14Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 15Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 16Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 17Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 18Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 19Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 20Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 21Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 22Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 23Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 24Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 25Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 26Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 27Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 28Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 29Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 30
(Date:10/17/2014)... 17, 2014   DaVita HealthCare Partners Inc. ... the nation,s largest and most innovative health care ... – the company,s award-winning, leadership development and cultural ... teammates from around the globe were in attendance ... Academy is a two-day one-of-a-kind experience for new ...
(Date:10/16/2014)... 16, 2014  Cepheid (Nasdaq: CPHD ) ... of $115.2 million, representing growth of 15% from $100.1 ... in the third quarter of 2014 was $(7.2) million, ... of $(1.4) million, or $(0.02) per share, in the ... compensation expense, amortization of debt discount and transaction costs, ...
(Date:10/16/2014)... Eight finalists, all representing outstanding innovation in pediatric medical ... a chance to compete for one of two $50,000 ... Annual Pediatric Surgical Innovation Symposium hosted by ... 2014. Selected from a competitive field of ... the finalists are: , Creative Vascular ...
Breaking Medicine Technology:DaVita HealthCare Partners Celebrates New-Teammate Training and Leadership Milestone 2DaVita HealthCare Partners Celebrates New-Teammate Training and Leadership Milestone 3Cepheid Reports 2014 Third Quarter Results 2Cepheid Reports 2014 Third Quarter Results 3Cepheid Reports 2014 Third Quarter Results 4Cepheid Reports 2014 Third Quarter Results 5Cepheid Reports 2014 Third Quarter Results 6Cepheid Reports 2014 Third Quarter Results 7Cepheid Reports 2014 Third Quarter Results 8Cepheid Reports 2014 Third Quarter Results 9Cepheid Reports 2014 Third Quarter Results 10Cepheid Reports 2014 Third Quarter Results 11Cepheid Reports 2014 Third Quarter Results 12Cepheid Reports 2014 Third Quarter Results 13Cepheid Reports 2014 Third Quarter Results 14Cepheid Reports 2014 Third Quarter Results 15Cepheid Reports 2014 Third Quarter Results 16Cepheid Reports 2014 Third Quarter Results 17Finalists for Children's National Health System pediatric medical device competition announced 2Finalists for Children's National Health System pediatric medical device competition announced 3Finalists for Children's National Health System pediatric medical device competition announced 4
... Oct. 19, 2011  CureFAKtor Pharmaceuticals, LLC, a privately-held biopharmaceutical ... Adhesion Kinase (FAK) inhibitors for cancer, announced today that ... present a company overview at the Biotechnology Industry Organization,s ... Francisco, CA on Wednesday, October 26 at 9:00 am. ...
... Oct. 19 2011 Varian Medical Systems (NYSE: ... X-Ray imaging technology, is announcing the publication of its ... company,s policies and achievements in extending care, protecting resources ... has been produced as part of the wider investment ...
Cached Medicine Technology:CureFAKtor Pharmaceuticals to Present at 10th Annual BIO Investor Forum 2Varian Medical Systems Publishes First Sustainability Report Outlining Environmental, Charitable, Safety and Health Access Achievements 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: